Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.57 |
| ▸ | NPC1 | O15118 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | HPGD | P15428 | 9/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.51 |
| ▸ | RELA | Q04206 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904181 | 0.86 | KDM4E (0.60) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11328720 | 0.85 | KDM4E (0.58) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11332226 | 0.85 | KDM4E (0.73) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5542189 | 0.84 | GAA (0.56) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4063835 | 0.82 | KDM4E (0.54) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22042899 | 0.82 | KDM4E (0.54) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30612631 | 0.82 | KDM4E (0.54) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13986779 | 0.82 | KDM4E (0.54) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23176649 | 0.81 | KDM4E (0.53) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5538663 | 0.81 | KDM4E (0.62) | RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008310-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008310-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-7842806-B2 | Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-7842806-B2 | Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | disclosed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20090048277-A1 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-02-19 | — | — | US | disclosed |
| US-20090048277-A1 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-02-19 | — | — | US | disclosed |
| EP-2020410-A1 | Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use | sanofi-aventis (FR) | 2009-02-04 | — | — | EP | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| WO-2007080324-A2 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | SANOFIS-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007003765-A1 | DERIVATIVES OF PYRIDO[2,3-D]PYRIMIDINE, THE PREPARATION THEREOF, AND THE THERAPEUTIC APPLICATION OF THE SAME | SANOFI AVENTIS (FR) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | RAB9A 3706/4885KDM4E 2063/4885NPC1 3257/4885 |
| US-20090048277-A1 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | DPYD, TYMP, PDXK | RAB9A 1594/4885KDM4E 2892/4885NPC1 3363/4885 |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | RAB9A 3706/4885KDM4E 2063/4885NPC1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.